Capecitabine Studied In Advanced Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

HOUSTON--A new tumor-selective agent may permit delivery of higher levels of 5-fluorouracil (5-FU) with lower toxicity, said Richard Pazdur, MD, of M.D. Anderson Cancer Center. A phase III trial of capecitabine is ongoing in colorectal cancer, and it is also under study for the treatment of breast cancer.

HOUSTON--A new tumor-selective agent may permit delivery of higher levelsof 5-fluorouracil (5-FU) with lower toxicity, said Richard Pazdur, MD,of M.D. Anderson Cancer Center. A phase III trial of capecitabine is ongoingin colorectal cancer, and it is also under study for the treatment of breastcancer.

Capecitabine, which has been developed by Hoffmann-LaRoche, is an oralfluoropyrimidine carbamate that is preferentially converted to 5-FU atthe tumor site, Dr. Pazdur said at the Chemotherapy Foundation Symposium.It undergoes a cascade of conversions from 5´DFCR to 5´-DFURand finally to 5-FU.

Its action depends on the presence of higher levels of pyrimidine nucleosidephosphorylase in tumors than in normal tissue. Taken orally, it passesthrough the intestinal mucosa intact due to its carbamate structure. Itis hoped that this will minimize the diarrhea associated with 5-FU anddoxifluridine (5´-DFUR), which releases 5-FU prodrug within the smallintestine.

The phase III trial is comparing an intermittent capecitabine schedulewith IV dosing of 5-FU and leucovorin in 524 colorectal cancer patients.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Related Content